Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs

Drug Saf. 1994 Feb;10(2):170-81. doi: 10.2165/00002018-199410020-00006.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with significant upper gastrointestinal (GI) toxicity, with a relative risk of approximately 3. This is supported by evidence drawn from randomised controlled trials [of aspirin (acetylsalicylic acid)], cohort studies and case-control studies. The risk is increased with higher doses of medication, shorter treatment duration and concomitant corticosteroid use. Elderly patients and those with a history of GI illness are also at increased risk. Ibuprofen may be associated with a lower, and piroxicam with a higher, risk of complications. There are only preliminary data regarding an association between NSAIDs and small and large intestinal complications. Therapeutic alternatives which may confer a lower risk of significant GI toxicity include enteric-coated preparations, non-acetylated salicylates, and NSAIDs taken in conjunction with misoprostol. Epidemiological data regarding these alternatives are sparse.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Case-Control Studies
  • Gastrointestinal Diseases / chemically induced*
  • Gastrointestinal Diseases / epidemiology*
  • Humans
  • Randomized Controlled Trials as Topic

Substances

  • Anti-Inflammatory Agents, Non-Steroidal